Literature DB >> 9667651

The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.

A S Levenson1, D A Tonetti, V C Jordan.   

Abstract

Oestrogens and antioestrogens modulate the synthesis of transforming growth factor alpha (TGF-alpha) in breast cancer cells. The purpose of the present report was to examine regulation of TGF-alpha gene expression by oestradiol (E2) and antioestrogens in MDA-MB-231 breast cancer cells transfected with either the wild-type or mutant oestrogen receptor (ER). We recently reported the concentration-dependent E2 stimulation of TGF-alpha mRNA in MDA-MB-231 ER transfectants (Levenson et al, 1997). We now report that 4-hydroxytamoxifen (4-OHT) shows oestrogen-like effects on the induction of TGF-alpha gene expression in our transfectants. Accumulation of TGF-alpha mRNA in response to both E2 and 4-OHT but not in response to the pure antioestrogen ICI 182,780 suggests that E2-ER and 4-OHT-ER complexes can bind to an oestrogen response element (ERE), located in the promoter region of the TGF-alpha gene and can activate transcription of the gene. Surprisingly, no activation of luciferase expression was observed after transient transfection of the TGF-alpha ERE/luciferase reporter constructs. Possible activation of an alternative ER-mediated pathway responsible for the regulation of TGF-alpha gene expression in the ER transfectants is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667651      PMCID: PMC2150359          DOI: 10.1038/bjc.1998.301

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  50 in total

1.  Estrogen induction of TGF-alpha is mediated by an estrogen response element composed of two imperfect palindromes.

Authors:  D El-Ashry; S A Chrysogelos; M E Lippman; F G Kern
Journal:  J Steroid Biochem Mol Biol       Date:  1996-11       Impact factor: 4.292

2.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

Authors:  C L Smith; Z Nawaz; B W O'Malley
Journal:  Mol Endocrinol       Date:  1997-06

3.  Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.

Authors:  J J Pink; V C Jordan
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

4.  Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.

Authors:  A S Levenson; W H Catherino; V C Jordan
Journal:  J Steroid Biochem Mol Biol       Date:  1997-03       Impact factor: 4.292

5.  Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene.

Authors:  N N Yang; M Venugopalan; S Hardikar; A Glasebrook
Journal:  Science       Date:  1996-08-30       Impact factor: 47.728

6.  A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.

Authors:  W H Catherino; D M Wolf; V C Jordan
Journal:  Mol Endocrinol       Date:  1995-08

7.  Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue.

Authors:  W H Catherino; V C Jordan
Journal:  Cancer Lett       Date:  1995-05-25       Impact factor: 8.679

8.  Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.

Authors:  M M Montano; K Ekena; K D Krueger; A L Keller; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1996-03

Review 9.  Possible mechanisms in the emergence of tamoxifen-resistant breast cancer.

Authors:  D A Tonetti; V C Jordan
Journal:  Anticancer Drugs       Date:  1995-08       Impact factor: 2.248

10.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.

Authors:  P Webb; G N Lopez; R M Uht; P J Kushner
Journal:  Mol Endocrinol       Date:  1995-04
View more
  13 in total

Review 1.  The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors:  D A Tonetti; V C Jordan
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.

Authors:  Philipp Y Maximov; Cynthia B Myers; Ramona F Curpan; Joan S Lewis-Wambi; V Craig Jordan
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

3.  Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors:  Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

4.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

5.  Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.

Authors:  J S Park; S Carter; D B Reardon; R Schmidt-Ullrich; P Dent; P B Fisher
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

6.  Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death.

Authors:  P Dent; D B Reardon; J S Park; G Bowers; C Logsdon; K Valerie; R Schmidt-Ullrich
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

Review 7.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

8.  Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.

Authors:  Bethany K Asare; Emmanuel Yawson; Rajendram V Rajnarayanan
Journal:  Cell Cycle       Date:  2017-07-19       Impact factor: 4.534

9.  Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

Authors:  S Sengupta; I Obiorah; P Y Maximov; R Curpan; V C Jordan
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Identification of estrogen-responsive genes involved in breast cancer metastases to the bone.

Authors:  Jun Wang; Jennifer Jarrett; Chiang-Ching Huang; Robert L Satcher; Anait S Levenson
Journal:  Clin Exp Metastasis       Date:  2007-06-26       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.